HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Abstract Full Text (PDF) Submit a Letter to Editor Alert me when this article is cited Alert me when eLetters are posted Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Tintut, Y. Articles by Demer, L. L. Search for Related Content PubMed PubMed Citation Articles by Tintut, Y. Articles by Demer, L. L. Social Bookmarking                      What's this?

J Biol Chem, Vol. 273, Issue 13, 7547-7553, March 27, 1998

cAMP Stimulates Osteoblast-like Differentiation of Calcifying Vascular Cells
POTENTIAL SIGNALING PATHWAY FOR VASCULAR CALCIFICATION^*

Yin Tintut, Farhad Parhami, Kristina Boström, Simon M. Jackson, and Linda L. Demer

From the Division of Cardiology, Departments of Medicine and Physiology, UCLA School of Medicine, Los Angeles, California 90095-1679

	ABSTRACT

Top Abstract Introduction Procedures Results Discussion References

The role of the cAMP signaling pathway in vascular calcification was investigated using calcifying vascular cells (CVC) derived from primary aortic medial cell cultures. We previously showed that CVC have fibroblastic morphology and express several osteoblastic differentiation markers. After confluency, they aggregate into cellular condensations, which later mature into nodules where mineralization is localized. Here, we investigated the effects of cAMP on CVC differentiation because it plays a role in both osteoblastic differentiation and vascular disease. Dibutyryl-cAMP or forskolin treatment of CVC for 3 days induced osteoblast-like "cuboidal" morphology, inhibited proliferation, and enhanced alkaline phosphatase activity, all early markers of osteoblastic differentiation. Isobutylmethylxanthine and cholera toxin had the same effects. Treatment of CVC with pertussis toxin, however, did not induce the morphological change or increase alkaline phosphatase activity, although it inhibited CVC proliferation to a similar extent. cAMP also increased type I procollagen production and gene expression of matrix -carboxyglutamic acid protein, recently shown to play a role in in vivo vascular calcification. cAMP inhibited the expression of osteopontin but did not affect the expression of osteocalcin and core binding factor. Prolonged cAMP treatment enhanced matrix calcium-mineral incorporation but inhibited the condensations resulting in diffuse mineralization throughout the monolayer of cells. Treatment of CVC with a protein kinase A-specific inhibitor, KT5720, inhibited alkaline phosphatase activity and mineralization during spontaneous CVC differentiation. These results suggest that the cAMP pathway promotes in vitro vascular calcification by enhancing osteoblast-like differentiation of CVC.

	INTRODUCTION

Top Abstract Introduction Procedures Results Discussion References

Arterial calcification is a common and clinically significant complication associated with atherosclerosis (1, 2). Hoeg and colleagues showed that calcific atherosclerosis is significant in patients with homozygous familial hypercholesterolemia (3). Previously, we found expression of bone morphogenetic protein (BMP-2), a potent bone differentiation factor that drives endochondral bone formation (4) in human calcified plaque (5).

Previously we isolated subpopulations of cells from the bovine artery wall that aggregate into mesenchymal condensations that later mature into mineralized multicellular nodules (6). Although nodules occasionally form in primary smooth muscle cells culture, these calcifying vascular cell (CVC)¹ cultures differ from primary smooth muscle cell cultures in an approximately 10-fold enrichment for nodule formation as well as the expression of molecular markers such as osteopontin, type I collagen, and the epitope for monoclonal antibody 3G5 (6). CVC retain their phenotype through multiple passages, and they exhibit several osteoblastic markers including type I collagen (Coll I), alkaline phosphatase, osteopontin, and osteocalcin (6). Certain agents present in atherosclerotic arteries, such as 25-hydroxycholesterol, transforming growth factor -1, and lipid oxidation products, such as minimally oxidized low density lipoprotein and 8-isoprostaglandin E₂, promote CVC differentiation (6, 7).

Other cloned subpopulations of artery wall cells do not form nodules even in prolonged culture conditions, suggesting that CVC represent a specific subpopulation (6). There are intriguing similarities between CVC and the mesenchymal stem cells present in adult nonhematopoietic tissue (8-10) that are capable of differentiating into osteoblasts, chondroblasts, adipocytes, and myoblasts. Such cells may account for pathologic calcification in other mesenchymal tissues.

The cAMP signaling pathway plays a role in both osteoblast differentiation and vascular disease. In osteoblasts, parathyroid hormone modulates differentiation via the cAMP-mediated pathway (11, 12). cAMP functional response elements have been reported in promoter regions of osteoblast associated genes (13-15). In vascular smooth muscle cells, stimulation of cAMP inhibits proliferation, relaxation, and migration (16-18). In addition, the cAMP pathway is involved in activation of endothelial cells by oxidized lipoproteins (19). Levels of cAMP are also significantly increased in atherosclerotic lesions and aortas of animals on a high cholesterol diet (20, 21).

During osteoblast development, a series of events occurs as cells undergo differentiation (22). Proliferation declines before the onset of differentiation, and various osteoblastic marker genes, involved in extracellular matrix development and mineralization, are expressed in waves: Coll I is expressed maximally during proliferation and declines progressively, whereas alkaline phosphatase and matrix GLA protein (MGP) expression start low and peak during the matrix development/maturation stage, and osteopontin and osteocalcin expression increase and reach a maximum during the matrix mineralization stage (22, 23).

Because the cAMP pathway plays a role in both osteoblast differentiation and vascular disease, we investigated its regulatory function in CVC differentiation. In this report, we show that the cAMP pathway stimulates the osteoblast-like differentiation of CVC by inducing morphological change, inhibiting proliferation, enhancing osteoblastic markers (alkaline phosphatase, matrix GLA protein, and type I procollagen), and increasing matrix calcium incorporation yet inhibiting CVC condensation resulting in a diffuse pattern of mineralization.

	EXPERIMENTAL PROCEDURES

Top Abstract Introduction Procedures Results Discussion References

Materials-- [³H]Thymidine, ⁴⁵CaCl₂ and [³²P]dCTP were from Amersham Corp. Dibutyryl cAMP, forskolin, cholera toxin, isobutylmethylxanthine, pertussis toxin, and a protein kinase A-specific inhibitor, KT5720, were from Calbiochem (San Diego, CA). The -glycerophosphate was purchased from Sigma. Human osteopontin (24) and human type 1(I) collagen cDNA (25) probes for Northern analysis were from American Tissue Culture Collection, and human 28 S rRNA probe was purchased from CLONTECH (Palo Alto, CA). Type I procollagen polyclonal antibody for Western analysis was from Chemicon International Inc. (Temecula, CA).

Cell Culture-- CVC, the clonal subpopulation of primary bovine aortic smooth muscle cells, were identified as described previously (6). CVC were grown in Dulbecco's modified Eagle's medium (Irvine Scientific, Santa Ana, CA) containing 15% heat-inactivated fetal bovine serum (Hyclone Labs, Logan, UT) and supplemented with sodium pyruvate (1 mM), penicillin (100 units/ml), and streptomycin (100 units/ml), all from Irvine Scientific, CA. The medium was changed every 3-4 days with agents, if applicable. From 5-7 days before von Kossa staining, 5 mM -glycerophosphate (7) and 4 mM CaCl₂ were added to the media to permit maximal mineralization.

[³H]Thymidine Incorporation-- CVC seeded in 24-well plates were treated at 70-90% confluence for 24 h with dibutyryl cAMP (1 mM), forskolin (25 µM), or control media (sterile water for db-cAMP and 0.1% Me₂SO for forskolin). [³H]Thymidine was added at 1 mCi/ml for an additional 24 h, and [³H]thymidine incorporation was determined as described previously (26). The data were shown as the means ± S.D. of 6 wells.

Western Analysis-- Cells grown in duplicate 100-mm dishes were treated with forskolin (25 µM) for 3 days. Cells were washed twice and scraped in phosphate-buffered saline. The cell pellet was lysed in lysis buffer containing protease inhibitors (10 mM HEPES, pH 7.5, 200 mM NaCl, 2 mM CaCl₂, 1.5% Triton X-100, 0.5 mg/liter leupeptin, 1 mM EDTA, 0.7 mg/liter pepstatin, 0.2 mM phenylmethylsulfonyl fluoride) and sonicated. The cell debris was pelleted, and the total protein concentration was measured using the Pierce assay. Protein (5 µg) was isolated on 8% Tris-glycine gel (Novex, San Diego, CA) and electro-transferred to nitrocellulose membrane overnight at 4 °C. The blots were probed with rabbit anti-bovine collagen type I polyclonal antibody at 1:100 dilution for 2 h at room temperature. The 1 ° antibody was detected by enhanced chemiluminescence (Amersham Corp.).

Alkaline Phosphatase Activity Assay-- CVC seeded in 24-well plates were treated with vehicle alone or cAMP agonists at subconfluence for 3 days, and alkaline phosphatase assay was performed as described previously (7). The alkaline phosphatase activity was normalized to total protein concentration determined using the Bradford (Bio-Rad) assay. The data were from a representative of two experiments shown as the means ± S.D. of quadruplicate wells.

RNA Isolation and Northern Analysis-- For spontaneous CVC differentiation, CVC were grown in duplicate 60-mm dishes for the indicated time, and total RNA was isolated (Stratagene, La Jolla, CA). During the nodule forming stage, cells were suspended in 1× trypsin-EDTA, and nodules were separated by filtration. The nodules were washed twice, and total RNA from both nodules and flow-through monolayer cells were extracted. For the cAMP treatments, CVC were grown in duplicate 60-mm dishes and vehicle alone, dibutyryl cAMP (1 mM), or forskolin (25 µM) were added at subconfluent stage. After 3 days of culture, total RNA was isolated. Total RNA (10 µg) in duplicate samples were run on 1% agarose/formaldehyde gels and transferred overnight to nitrocellulose membranes, which were cross-linked with UV light. The membranes were hybridized overnight at 58 °C with ³²P-labeled human osteopontin cDNA probe prepared according to protocols by Prime-It II random primer labeling kit (Stratagene). The membranes were washed twice at room temperature for 20 min with 2× SSC with 0.2% SDS and twice at 58 °C for 20 min with 1× SSC with 0.2% SDS before autoradiography. After stripping with 0.1× SSC with 0.1% SDS, the same membranes were probed with human type I collagen using the same conditions or with human 28 S rRNA using 55 °C hybridization overnight and washing with 2× SSC with 0.1% SDS for 5 min at room temperature once and 0.5× SSC with 0.1% SDS for 30 min twice at 55 °C.

RT-PCR of cDNA-- The RNA isolated as described above (3 µg) was reverse-transcribed in 50 µl of reaction buffer (Stratagene) containing 0.5 mM of each dNTP (Pharmacia Biotech Inc.), 50-80 units RNase Block (Stratagene), 50 units of Moloney murine leukemia virus reverse transcriptase (Stratagene) and 750 ng of oligo(dT) (random hexamer; Boehringer-Mannheim) for 90 min at 37 °C.

PCR (GeneAmp PCR system 2400, Perkin-Elmer) using primers specific for each gene (alkaline phosphatase, osteocalcin, matrix GLA protein, Cbfa-1, and GAPDH) were carried out in a volume of 10 µl with 1× Pfu polymerase buffer (Stratagene), 190 µM of dNTP, 28 ng of each primer, 0.45 units of Pfu polymerase (Stratagene), 0.18 µCi of [-³²P]dCTP and 1.0 µl of template (from above 50 µl RT reaction). Thermal cycling was carried out for 21 cycles (GAPDH) or 30 cycles (alkaline phosphatase, osteocalcin, MGP, and Cbfa-1) at 62 °C annealing temperature for alkaline phosphatase, MGP, Cbfa-1, and GAPDH and 72 °C for osteocalcin. Amplified fragments were isolated on polyacrylamide gel (29:1 acrylamide to bis-acrylamide), and the autoradiographs were scanned with AGFA ARCUS II scanner and semi-quantitated with NIH Image software, version 1.49, public domain program.²

⁴⁵Ca Incorporation Assay and von Kossa Staining-- ⁴⁵Ca incorporation and von Kossa staining to detect mineralization was performed as described previously (7). The data for ⁴⁵Ca incorporation were from a representative of two experiments shown as the means ± S.D. of 6 wells.

	RESULTS

Top Abstract Introduction Procedures Results Discussion References

Spontaneous Differentiation of CVC

Morphology-- During spontaneous differentiation, CVC displayed distinct morphological transitions. In post-confluent cultures (5-7 days after plating), cells aggregated into ridge-like structures closely resembling embryonic condensations (arrows, Fig. 1B). From 9-11 days after plating, these condensations formed multicellular nodules (arrow, Fig. 1C), which became increasingly darkened after 14-16 days in culture due to mineralization, identified by strongly positive von Kossa staining (arrow, Fig. 1D).

View larger version (108K): [in this window] [in a new window]   Fig. 1.   Effect of cAMP on morphological change. CVC at 70-90% confluence were treated with control medium (A-D) or medium containing 1 mM db-cAMP (E-H). Phase contrast (magnification, ×40) shows a change from an elongated (A) to a cuboidal morphology (E) after 2 days in culture. After 6 days in culture, condensations were observed in control (arrows, B) but not in the treated cells (F); after 10 days in culture nodules were observed in control (arrow, C) but not in the treated cells (G). After 15 days in culture, cells were stained with the von Kossa, which identifies calcium mineral as black. Calcification is localized within nodules in control (arrow, D) but diffuse in db-cAMP-treated cells (H).

Expression of Osteoblastic Differentiation Markers-- Previously we reported that CVC exhibit several osteoblastic differentiation markers (6). Here, we determined the time course of their expression during the stages described above (Fig. 1, A-D). Total RNA was isolated from duplicate dishes at stages of subconfluence (1 day after plating), confluence (3 days after plating), condensation (6 days after plating), nodules (10 days after plating), and calcification (14 days after plating).

Type I procollagen, osteopontin, and 28 S rRNA (used as an internal control) expression were determined by Northern analyses. Alkaline phosphatase, matrix GLA protein, osteocalcin, Cbfa-1, and GAPDH (an internal control) were determined by RT-PCR with specific primers designed for each gene (Fig. 2A). For semiquantitative RT-PCR, amplification cycles were chosen to be within the linear range (data not shown).

View larger version (25K): [in this window] [in a new window]   Fig. 2.   Expression of osteoblastic differentiation markers during spontaneous CVC differentiation. A, total RNA at the same time points shown in Fig. 1 were isolated, and gene expression of Coll I, osteopontin, and 28 S rRNA were analyzed by Northern analysis; alkaline phosphatase, matrix GLA protein, Cbfa-1, and GAPDH expression were analyzed by RT-PCR. For the subconfluence stage, RNA was isolated 1 day post-plating. d, day(s); subconf, subconfluence; conf, confluence; cond, condensation; nod, nodules; calc, calcification. B, the densitometric data of scanned autoradiographs, normalized for 28 S rRNA (for osteopontin and Coll I) or GAPDH (for alkaline phosphatase, matrix GLA protein, osteocalcin, and Cbfa-1), was plotted as the percentage of maximum expression (average of duplicate samples) over the number of days in culture that represent each differentiation stage.

Autoradiographs shown in Fig. 2A were scanned, and data were plotted as the percentage of maximum expression over the number of days in culture that correspond to the stages shown in Fig. 1 (A-D) and subconfluence (1 day post-plating; not shown). Coll I, alkaline phosphatase, matrix GLA protein, and osteocalcin expression increased as CVC underwent distinct morphological transitions, whereas osteopontin expression declined progressively (Fig. 2, A and B). Cbfa-1 was expressed constitutively during CVC differentiation (Fig. 2, A and B).

To determine whether the expression of these differentiation markers during the later stages of CVC was limited to the cells within the nodules and not in the intervening monolayer cells, nodules were separated from the intervening cells by suspension and filtration, and total RNA from both sets were extracted. Results showed that all differentiation markers except MGP were expressed at similar levels in both the monolayer and the cells forming nodules (Table I). MGP was expressed at 3-fold higher levels in the nodules than in the monolayer cells.

View this table: [in this window] [in a new window]   Table I Distribution of osteoblastic differentiation markers between nodules versus intervening monolayer cells Nodules were separated from monolayer cells by filtration, and expression levels were determined from both RNA derived from the nodules and that from the monolayer cells. The expression found in nodules is expressed as a percentage of the total.

Effect of cAMP on Osteoblast-like Differentiation of CVC

Morphology-- Short term treatment of CVC with 1 mM db-cAMP in a single administration at 70-90% confluence and incubated for 2 days induced a morphological change from an elongated to a "cuboidal" shape (Fig. 1, E versus A, control), which is an indication of preosteoblast differentiation into osteoblastic cells (27-29). The same morphological change was observed when CVC were treated with forskolin (25 µM), isobutylmethylxanthine (200 µM), or cholera toxin (500 ng/ml) (data not shown).

Prolonged treatment of CVC with db-cAMP has marked effects on later differentiation stages of CVC, including condensation, nodule formation, and mineralization. When CVC were treated with 1 mM db-cAMP (at 70-90% confluence and fed every 3-4 days with fresh medium containing 1 mM db-cAMP), there was inhibition of condensation (Fig. 1: control (B) versus treated cells (F) after 6 days in culture) and subsequent nodule formation (control (C) versus treated cells (G) after 10 days in culture). However, von Kossa staining for mineralization showed that calcification occurred in both treated and control cells after 15 days in culture (control (D) versus treated cells (H). In control cells, calcification was confined within nodules, whereas in treated cells, calcification was diffuse throughout the monolayer with some patches of increased density, despite the absence of nodules.

Proliferation-- Cells were treated with 1 mM db-cAMP or 25 µM forskolin at 70-90% confluency and incubated for 2 days. [³H]Thymidine was added to the medium during the last 24 h, and cellular proliferation was assessed (prior to condensation and nodule formation). The results showed that increased cAMP inhibited CVC proliferation (Fig. 3). Because it has been shown in osteoblasts that the decline of proliferation is functionally coupled to the onset of differentiation (22), we investigated whether cAMP stimulation also initiated expression of osteoblastic differentiation markers.

View larger version (67K): [in this window] [in a new window]   Fig. 3.   Effect of cAMP on DNA synthesis. [3H]Thymidine incorporation of CVC treated at 70-90% confluence for 2 days with db-cAMP (1 mM), forskolin (25 µM), or control medium (controls) is shown. Cells were pulsed with [3H]thymidine during the last 24 h prior to the assay.

Osteoblastic Differentiation Markers-- Alkaline phosphatase activity, a well recognized early marker of osteoblastic differentiation (30), increased during spontaneous CVC differentiation (7). Therefore, we first measured its activity in response to cAMP stimulation. CVC at 70-90% confluence were treated with various concentrations of db-cAMP or forskolin and incubated for 3 days. Alkaline phosphatase activity was dose-dependently induced (Fig. 4, A and B, respectively). In addition, cholera toxin (500 ng/ml) and isobutylmethylxanthine (200 µM), other agents known to increase intracellular cAMP levels, also had similar effects on alkaline phosphatase activity (Fig. 4C).

View larger version (23K): [in this window] [in a new window]   Fig. 4.   Effect of cAMP on induction of alkaline phosphatase activity. CVC at 70-90% confluence were treated for 3 days with db-cAMP (0, 0.063, 0.25, and 1 mM) (A), forskolin (0, 1.56, 6.25, and 25 µM) (B), and db-cAMP (1 mM), forskolin (25 µM), cholera toxin (500 ng/ml), isobutylmethylxanthine (IBMX, 200 µM), or control medium (cont) (C). Alkaline phosphatase (ALP) activity from whole cell lysates was measured. Activity was normalized for total protein concentration.

Because the results showed that cAMP induced early makers of osteoblast-like differentiation in CVC, we next determined its effects on later markers described above. Duplicate dishes of CVC were treated at 70-90% confluence with 1 mM db-cAMP or 25 µM forskolin and incubated for 3 days, and total RNA was analyzed by Northern analysis or RT-PCR as described above. Treatment with either agent caused increased gene expression of alkaline phosphatase (11- and 8-fold, respectively) and matrix GLA protein (4- and 2-fold, respectively) but a decrease in osteopontin expression (Fig. 5A). cAMP had no effect on the expression of osteocalcin and Cbfa-1 (data not shown). Type I collagen production was enhanced 2-fold as shown by Western analysis when cAMP was stimulated by 25 µM forskolin (Fig. 5B).

View larger version (84K): [in this window] [in a new window]   Fig. 5.   Effect of cAMP on expression of osteoblastic differentiation markers. A, RNA isolated from CVC treated with db-cAMP (1 mM) or forskolin (25 µM) for 3 days were analyzed by either Northern analysis (osteopontin and 18 S rRNA) or RT-PCR (alkaline phosphatase, matrix GLA protein, and GAPDH). B, whole cell lysate from CVC treated with forskolin (25 µM) for 3 days were analyzed by Western. Type I procollagen probed with anti-bovine polyclonal antibody was detected as two bands representing 1(I) and 2(I) chains. cont, control.

Mineralization-- To quantify the amount of mineralization in both control and treated cells, radiolabeled calcium incorporation was measured. CVC were treated with 1 mM db-cAMP at 70-90% confluence and fed every 3-4 days with fresh medium containing 1 mM db-cAMP or control media. After 7 days in culture, 4 mM CaCl₂ and 5 mM -glycerophosphate were added to the media to enhance mineralization. After an additional 6-7 days in culture, cells were washed twice and changed to media containing 5 mM -glycerophosphate, labeled calcium (⁴⁵CaCl₂), and either 1 mM db-cAMP or control medium and incubated for an additional 48 h. In validation studies, incorporated labeled calcium has been shown to represent primarily matrix-bound calcium, because similar results were obtained in cultures permeabilized with Triton X-100, which removes ionic calcium (7). The results showed that calcium incorporation was enhanced approximately 4-fold with db-cAMP treatment (Fig. 6).

View larger version (45K): [in this window] [in a new window]   Fig. 6.   Effect of prolonged cAMP stimulation on CVC mineralization. Calcium mineral deposition was assayed by 45Ca incorporation in CVCs treated with repeated doses of db-cAMP over a 15-day period as described in the text.

Relationship between Differentiation and Proliferation-- Because osteoblastic differentiation has been considered functionally coupled to inhibition of proliferation, we assessed whether inhibition of CVC proliferation is sufficient to promote osteoblast-like differentiation. CVC were treated with pertussis toxin, which has been shown to inhibit smooth muscle cell proliferation (at 0.001-100 ng/ml) without affecting cell viability and the level of intracellular cAMP (31). The results showed that pertussis toxin inhibited CVC proliferation (87% at 20 ng/ml; 89% at 100 ng/ml) without inducing cuboidal morphology or significantly increasing alkaline phosphatase activity (2-fold increase at both concentrations of pertussis toxin), suggesting that the inhibition of proliferation is not sufficient to promote osteoblast-like differentiation of CVC.

To further determine whether blocking the cAMP pathway decreases osteoblast-like differentiation, CVC were treated at 70-90% confluence with 10 µM KT5720, previously used as a protein kinase A-specific inhibitor (32, 33). Results showed that the increase in alkaline phosphatase activity during spontaneous CVC differentiation was blocked (>90% inhibition; data not shown). In addition, Ca⁴⁵ incorporation assay showed that mineralization was also inhibited (>80% inhibition; data not shown), suggesting that the cAMP pathway has a direct effect on osteoblast-like differentiation of CVC independent of its effect on proliferation.

To assess whether cAMP induces osteoblast-like differentiation in non-CVC, a subpopulation of primary smooth muscle cells that do not form nodules, two clones were treated with forskolin. The results showed that proliferation was inhibited approximately 70% without inducing a significant increase in alkaline phosphatase activity: at 3 days, the same dose of forskolin that caused a 20-fold increase in alkaline phosphatase activity in CVC caused only a 2-3-fold increase in non-CVC (data not shown). Even with 5 days of forskolin treatment, the effect on alkaline phosphatase activity in non-CVC did not increase further relative to control (data not shown). These results support a direct role of the cAMP pathway in osteoblast-like differentiation of CVC.

	DISCUSSION

Top Abstract Introduction Procedures Results Discussion References

These findings indicate that short term cAMP treatment (3 days) triggered the onset of osteoblast-like differentiation of CVC in several aspects: 1) induction of a morphological change, which is characteristic of preosteoblasts differentiating into osteoblasts (27-29); 2) inhibition of CVC proliferation, which is considered a requirement for the initiation of differentiation (22); 3) acceleration of the induction of osteoblastic differentiation markers including alkaline phosphatase, type I procollagen, and matrix GLA protein, which were also found to increase during spontaneous CVC differentiation; and 4) acceleration of the decline in osteopontin expression, which also occurs in spontaneous CVC differentiation.

The results further showed that long term cAMP treatment altered the mineralization pattern in CVC. During spontaneous differentiation, CVC aggregate to form condensations that mature into mineralized nodules. Prolonged treatment of CVC with db-cAMP inhibited condensation and subsequent nodule formation. Therefore, in cAMP-treated cells, enhanced production of alkaline phosphatase, extracellular matrix components, and increased matrix calcium incorporation were no longer confined to the nodules, as in the case with control cells, resulting in a diffuse pattern of mineralization throughout the monolayer. This diffuse pattern was not perfectly homogeneous, having some patchy areas of increased density, despite absence of nodules. This pattern has intriguing similarities to in vitro mineralization of bone cell lines (7).

The mechanism by which cAMP blocks condensation is not known but may be related to elimination of a chemotactic gradient (34) and/or altered expression of adhesion molecules such as hyaluronan, clusterin, or N-CAM, which have been suggested to regulate aggregation (35, 36). The inhibition of condensation by cAMP may also occur through effects on the proliferation signal that precedes aggregation in many epithelial-mesenchymal interactions and probably provides the critical density or quorum of cells required for condensation (35).

Previously, we showed the similarities between CVC and osteoblastic cells. Our present data reveal that the time course of expression of osteoblastic markers in CVC differs from that previously shown for bone cells by Stein, Lian, and co-workers (22). The most evident differences are in osteopontin and collagen I expression. In CVC, osteopontin expression declines progressively, whereas in osteoblastic cultures, its expression increases progressively, peaking during the late stage (matrix maturation stage) of osteoblast-like differentiation. In contrast, in CVC, type I procollagen expression increases progressively peaking during the late stage, but in osteoblastic cultures, its expression declines progressively during differentiation (22). We have hypothesized that reciprocal responses of vascular and bone cells to lipid exposure may have a role in the simultaneous occurrence of vascular calcification and osteoporosis in humans (7) and in essential fatty acid-deficient mice (37).

The role of some of the osteoblastic differentiation markers in mineralization is still unclear. Much evidence points to control of formation and maturation of extracellular matrix, providing an environment that facilitates mineral deposition (22, 38). Our data indicate that the expression of one of these proteins, osteopontin, decreases with spontaneous CVC differentiation and in response to cAMP stimulation, whereas it increases in atherosclerotic calcification (39, 40). The increased expression of osteopontin in human atherosclerotic plaques, however, is largely attributable to other cell types, particularly the macrophage-derived foam cells (39, 41), which synthesize osteopontin as an early inflammatory response to tissue injury (42) and use osteopontin also as an opsonin for adhesion to and phagocytosis of calcified particulate matter (43). In areas of plaque composed of predominantly smooth muscle cells, osteopontin expression was not detected (39).

Another osteoblastic marker, matrix GLA protein, increases during CVC differentiation and in response to cAMP stimulation. This is consistent with previous reports of increased MGP expression predominantly by vascular smooth muscle cells in atherosclerotic lesions (39). These results may initially appear paradoxical in light of the recent report from Luo and colleagues demonstrating extensive vascular calcification and ossification in MGP null mouse (44). One might expect a decrease in MGP in association with in vitro vascular calcification. However, there are other examples such as leukocytosis, when a stimulus induces its own inhibitory factor. That is, absence of white cells in immunodeficient mice allows extensive infection; yet, in human infection, white cells are increased rather than absent. Likewise, absence of MGP in the knock-out mice allows extensive vascular calcification; yet, in human vascular calcification, MGP expression is increased rather than absent. Thus, MGP may be up-regulated in response to vascular calcification, perhaps to limit its extent.

In conclusion, these results support the hypothesis that cAMP modulates in vitro vascular calcification. The findings in atherosclerotic calcification are consistent with the findings in CVC, both in spontaneous and cAMP-induced differentiation, supporting the in vivo relevance of this model.

	ACKNOWLEDGEMENTS

We thank Dr. J. Berliner for comments and suggestions and V. Le and L. Tacvorian for technical assistance.

	FOOTNOTES

^* This work was supported by National Institutes of Health Grant HL30568, the Streisand Research Fund of the Lincy Foundation, the Stein-Oppenheimer Award, and the Laubisch Fund.The costs of publication of this article were defrayed in part by the payment of page charges. The article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

To whom correspondence should be addressed: Div. of Cardiology, UCLA School of Medicine, 47-123 Center for the Health Sciences, 10833 Le Conte Ave., Los Angeles, CA 90095-1679.

¹ The abbreviations used are: CVC, calcifying vascular cell(s); Coll I, type I collagen; GLA, -carboxyglutamic acid; MGP, matrix GLA protein; RT, reverse transcription; PCR, polymerase chain reaction; GAPDH, glyceraldehyde 3-phosphate dehydrogenase; Cbfa-1, core binding factor 1; db-cAMP, dibutyryl cAMP.

² Internet address: http://rsb.info.nih.gov/nih-image/.

	REFERENCES

Top Abstract Introduction Procedures Results Discussion References

1. Honye, J., Mahon, D. J., Jian, A., White, C., Ramee, S. R., Wallis, J. B., Al-Zarka, A., Tobis, J. M. (1992) Circulation 85, 1012-1025[Abstract/Free Full Text]
2. Farb, A., Burke, A. P., Tang, A. L., Liang, Y. H., Mannan, P., Smialek, J., Virmani, R. (1996) Circulation 93, 1354-1363[Abstract/Free Full Text]
3. Hoeg, J. M., Feuerstein, I. M., and Tucker, E. E. (1994) Arterioscler. Thromb. 14, 1066-1074[Abstract/Free Full Text]
4. Reddi, A. H., and Cunningham, N. S. (1993) J. Bone Miner. Res. 8, (suppl.) 499-502
5. Bostrom, K., Watson, K. E., Horn, S., Wortham, C., Herman, I. M., Demer, L. L. (1993) J. Clin. Invest. 91, 1800-1809
6. Watson, K., Bostrom, K., Ravindranath, R., Lam, T., Norton, B., and Demer, L. L. (1994) J. Clin. Invest. 93, 2106-2113
7. Parhami, F., Morrow, A. D., Balucan, J., Leitinger, N., Watson, A. D, Tintut, Y., Berliner, J. A., Demer, L. L. (1997) J. Arterioscler. Thromb. 17, 680-687 [Abstract/Free Full Text]
8. Prockop, D. J. (1997) Science 276, 71-74[Abstract/Free Full Text]
9. Dennis, J. E., and Caplan, A. I. (1996) Connect. Tissue Res. 35, 93-99[Medline] [Order article via Infotrieve]
10. Bruder, S. P., Fink, D. J., and Caplan, A. I. (1994) J. Cell. Biochem. 56, 283-294[Medline] [Order article via Infotrieve]
11. Partridge, N. C., Bloch, S. R., and Pearman, A. T. (1994) J. Cell. Biochem. 55, 321-327[CrossRef][Medline] [Order article via Infotrieve]
12. Siddhanti, S. R., and Quarles, L. D. (1994) J. Cell. Biochem. 55, 310-320[CrossRef][Medline] [Order article via Infotrieve]
13. Pearman, A. T., Chou, W.-Y., Bergman, K. D., Pulumati, M. R., Partridge, N. C. (1996) J. Biol. Chem. 271, 25715-25721[Abstract/Free Full Text]
14. Povinelli, C. M., Stewart, J. M., and Knoll, B. J. (1992) Biochim. Biophys. Acta 1115, 243-251[Medline] [Order article via Infotrieve]
15. Towler, D. A., and Rodan, G. A. (1995) Endocrinology 136, 1089-1096[Abstract]
16. Dubey, R. K., Mi, Z., Gillespie, D. G., Jackson, E. K. (1996) Hypertension 28, 765-771[Abstract/Free Full Text]
17. Galle, J., Bauersachs, J., Busse, R., and Bassenge, E. (1992) Arteriosclerosis and Thrombosis 12, 180-186[Abstract/Free Full Text]
18. Mooradian, D. L., Fernandes, B., Diglio, C. A., Lester, B. R. (1995) J. Cardiovasc. Pharmacol. 25, 611-618[Medline] [Order article via Infotrieve]
19. Parhami, F., Fang, Z. T., Fogelman, A. M., Andalibi, A., Territo, M. C., Berliner, J. A. (1993) J. Clin. Invest. 92, 471-478
20. Augustyn, J. M., and Zeigler, F. (1975) Science 187, 449-450[Abstract/Free Full Text]
21. Langner, R. O., Bement, C. L., and Pepin, J. M. (1996) Res. Commun. Mol. Pathol. Pharmacol. 94, 193-202[Medline] [Order article via Infotrieve]
22. Stein, G. S., Lian, J. B., Stein, J. L., Van Wijnen, A. J., Montecino, M. (1996) Physiol. Rev. 76, 593-629[Abstract/Free Full Text]
23. Barone, L. M., Owen, T. A., Tassinari, M. S., Bortell, R., Stein, G. S., Lian, J. B. (1991) J. Cell. Biochem. 46, 351-365[CrossRef][Medline] [Order article via Infotrieve]
24. Young, M. F., Kerr, J. M., Termine, J. D., Wewer, U. M., Wang, M. G., McBride, O. W., Fisher, L. W. (1990) Genomics 7, 491-502[CrossRef][Medline] [Order article via Infotrieve]
25. Kiefer, M. C., Saphire, A. C. S., Bauer, D. M., Barr, P. J. (1990) Nucleic Acids Res. 18, 1909[Free Full Text]
26. Noda, M., Vogel, R. L., Hasson, D. M., Rodan, G. A. (1990) Endocrinology 127, 185-190[Abstract/Free Full Text]
27. Maniatopoulos, C., Sodek, J., and Melcher, A. H. (1988) Cell Tissue Res. 254, 317-330[Medline] [Order article via Infotrieve]
28. Nefussi, J. R., Pouchelet, M., Collin, P., Sautier, J. M., Develay, G., Forest, N. (1989) Bone 10, 345-352[Medline] [Order article via Infotrieve]
29. Aubin, J. E., Liu, F., Malaval, L., and Gupta, A. K. (1995) Bone 17, (suppl.) 77-83
30. Dunlop, L. T., and Hall, B. K. (1995) Int. J. Dev. Biol. 39, 357-371[Medline] [Order article via Infotrieve]
31. Zhang, L. M., Newman, W. H., Castresana, M. R., Hildebrandt, J. D. (1994) Endocrinology 134, 1297-1304[Abstract/Free Full Text]
32. Bernabeu, R., Bevilaqua, L., Ardenghi, P., Bromberg, E., Schmitz, P., Bianchin, M., Izquierdo, I., and Medina, J. H. (1997) Proc. Natl. Acad. Sci. U. S. A. 94, 7041-7046[Abstract/Free Full Text]
33. Revan, S., Montesinos, M. C., Naime, D., Landau, S., and Cronstein, B. N. (1996) J. Biol. Chem. 271, 17114-17118[Abstract/Free Full Text]
34. Vicker, M. G. (1994) J. Cell Sci. 107, 659-667[Abstract]
35. Hall, B. K., and Miyake, T. (1992) Anat. Embryol. 186, 107-124[Medline] [Order article via Infotrieve]
36. Silkensen, J. R., Skubitz, K. M., Skubitz, A. P., Chmielewski, D. H., Manivel, J. C., Dvergsten, J. A., Rosenberg, M. E. (1995) J. Clin. Invest. 96, 2646-2653
37. Kruger, M. C., and Horrobin, D. F. (1997) Prog. Lipid Res. 36, 131-151[CrossRef][Medline] [Order article via Infotrieve]
38. Robey, P. G. (1996) Connect. Tissue Res. 35, 131-136[Medline] [Order article via Infotrieve]
39. Shanahan, C. M., Cary, N. R., Metcalfe, J. C., Weissberg, P. L. (1994) J. Clin. Invest. 93, 2393-2402
40. Giachelli, C. M., Bae, N., Almeida, M., Denhardt, D. T., Alpers, C. E., Schwartz, S. M. (1993) J. Clin. Invest. 92, 1686-1696
41. O'Brien, E. R., Garvin, M. R., Stewart, D. K., Hinohara, T., Simpson, J. B., Schwartz, S. M., Giachelli, C. M. (1994) Arterioscler. Thromb. 14, 1648-1656[Abstract/Free Full Text]
42. Giachelli, C. M., Liaw, L., Murry, C. E., Schwartz, S. M., Almeida, M (1995) Ann. N. Y. Acad. Sci. 760, 109-126[Medline] [Order article via Infotrieve]
43. McKee, M. D., and Nanci, A. (1996) Anat. Rec. 245, 394-409[CrossRef][Medline] [Order article via Infotrieve]
44. Luo, G., Ducy, P., McKee, M. D., Pinero, G. J., Loyer, E., Behringer, R. R., Karsenty, G. (1997) Nature 385, 78-81[CrossRef][Medline] [Order article via Infotrieve]

CiteULike

Complore

Connotea

Del.icio.us

Digg

Reddit

Technorati

This article has been cited by other articles:

				M. Mizobuchi, D. Towler, and E. Slatopolsky Vascular Calcification: The Killer of Patients with Chronic Kidney Disease J. Am. Soc. Nephrol., July 1, 2009; 20(7): 1453 - 1464. [Abstract] [Full Text] [PDF]

				M. Wan, C. Yang, J. Li, X. Wu, H. Yuan, H. Ma, X. He, S. Nie, C. Chang, and X. Cao Parathyroid hormone signaling through low-density lipoprotein-related protein 6 Genes & Dev., November 1, 2008; 22(21): 2968 - 2979. [Abstract] [Full Text] [PDF]

				J. J. Hsu, Y. Tintut, and L. L. Demer Vitamin D and Osteogenic Differentiation in the Artery Wall Clin. J. Am. Soc. Nephrol., September 1, 2008; 3(5): 1542 - 1547. [Abstract] [Full Text] [PDF]

				L. L. Demer and Y. Tintut Vascular Calcification: Pathobiology of a Multifaceted Disease Circulation, June 3, 2008; 117(22): 2938 - 2948. [Full Text] [PDF]

				R. Siddappa, A. Martens, J. Doorn, A. Leusink, C. Olivo, R. Licht, L. van Rijn, C. Gaspar, R. Fodde, F. Janssen, et al. cAMP/PKA pathway activation in human mesenchymal stem cells in vitro results in robust bone formation in vivo PNAS, May 20, 2008; 105(20): 7281 - 7286. [Abstract] [Full Text] [PDF]

				Y. Kanno, T. Into, C. J. Lowenstein, and K. Matsushita Nitric oxide regulates vascular calcification by interfering with TGF-{beta} signalling Cardiovasc Res, January 1, 2008; 77(1): 221 - 230. [Abstract] [Full Text] [PDF]

				Y. Yao, A. F. Zebboudj, A. Torres, E. Shao, and K. Bostrom Activin-like kinase receptor 1 (ALK1) in atherosclerotic lesions and vascular mesenchymal cells Cardiovasc Res, May 1, 2007; 74(2): 279 - 289. [Abstract] [Full Text] [PDF]

				I. Z. Jaffe, Y. Tintut, B. G. Newfell, L. L. Demer, and M. E. Mendelsohn Mineralocorticoid Receptor Activation Promotes Vascular Cell Calcification Arterioscler. Thromb. Vasc. Biol., April 1, 2007; 27(4): 799 - 805. [Abstract] [Full Text] [PDF]

				R. C. Johnson, J. A. Leopold, and J. Loscalzo Vascular Calcification: Pathobiological Mechanisms and Clinical Implications Circ. Res., November 10, 2006; 99(10): 1044 - 1059. [Abstract] [Full Text] [PDF]

				M. Abedin, J. Lim, T.B. Tang, D. Park, L.L. Demer, and Y. Tintut N-3 Fatty Acids Inhibit Vascular Calcification Via the p38-Mitogen-Activated Protein Kinase and Peroxisome Proliferator-Activated Receptor-{gamma} Pathways Circ. Res., March 31, 2006; 98(6): 727 - 729. [Abstract] [Full Text] [PDF]

				M. Morena, N. Terrier, I. Jaussent, H. Leray-Moragues, L. Chalabi, J.-P. Rivory, F. Maurice, C. Delcourt, J.-P. Cristol, B. Canaud, et al. Plasma Osteoprotegerin Is Associated with Mortality in Hemodialysis Patients J. Am. Soc. Nephrol., January 1, 2006; 17(1): 262 - 270. [Abstract] [Full Text] [PDF]

				K. Radcliff, T.-B. Tang, J. Lim, Z. Zhang, M. Abedin, L. L. Demer, and Y. Tintut Insulin-Like Growth Factor-I Regulates Proliferation and Osteoblastic Differentiation of Calcifying Vascular Cells via Extracellular Signal-Regulated Protein Kinase And Phosphatidylinositol 3-Kinase Pathways Circ. Res., March 4, 2005; 96(4): 398 - 400. [Abstract] [Full Text] [PDF]

				C. M. Giachelli Vascular Calcification Mechanisms J. Am. Soc. Nephrol., December 1, 2004; 15(12): 2959 - 2964. [Abstract] [Full Text] [PDF]

				J. L. Reynolds, A. J. Joannides, J. N. Skepper, R. McNair, L. J. Schurgers, D. Proudfoot, W. Jahnen-Dechent, P. L. Weissberg, and C. M. Shanahan Human Vascular Smooth Muscle Cells Undergo Vesicle-Mediated Calcification in Response to Changes in Extracellular Calcium and Phosphate Concentrations: A Potential Mechanism for Accelerated Vascular Calcification in ESRD J. Am. Soc. Nephrol., November 1, 2004; 15(11): 2857 - 2867. [Abstract] [Full Text] [PDF]

				M. Abedin, Y. Tintut, and L. L. Demer Mesenchymal Stem Cells and the Artery Wall Circ. Res., October 1, 2004; 95(7): 671 - 676. [Abstract] [Full Text] [PDF]

				V. M. Miller, G. Rodgers, J. A. Charlesworth, B. Kirkland, S. R. Severson, T. E. Rasmussen, M. Yagubyan, J. C. Rodgers, F. R. Cockerill III, R. L. Folk, et al. Evidence of nanobacterial-like structures in calcified human arteries and cardiac valves Am J Physiol Heart Circ Physiol, September 1, 2004; 287(3): H1115 - H1124. [Abstract] [Full Text] [PDF]

				Y. Tintut, Z. Alfonso, T. Saini, K. Radcliff, K. Watson, K. Bostrom, and L. L. Demer Multilineage Potential of Cells From the Artery Wall Circulation, November 18, 2003; 108(20): 2505 - 2510. [Abstract] [Full Text] [PDF]

				L. L. Demer and Y. Tintut Mineral Exploration: Search for the Mechanism of Vascular Calcification and Beyond: The 2003 Jeffrey M. Hoeg Award Lecture Arterioscler. Thromb. Vasc. Biol., October 1, 2003; 23(10): 1739 - 1743. [Abstract] [Full Text] [PDF]

				M. R. Davies, R. J. Lund, and K. A. Hruska BMP-7 Is an Efficacious Treatment of Vascular Calcification in a Murine Model of Atherosclerosis and Chronic Renal Failure J. Am. Soc. Nephrol., June 1, 2003; 14(6): 1559 - 1567. [Abstract] [Full Text] [PDF]

				G. A. Wong, V. Tang, F. El-Sabeawy, and R. H. Weiss BMP-2 inhibits proliferation of human aortic smooth muscle cells via p21Cip1/Waf1 Am J Physiol Endocrinol Metab, May 1, 2003; 284(5): E972 - E979. [Abstract] [Full Text] [PDF]

				M. Y. Speer, M. D. McKee, R. E. Guldberg, L. Liaw, H.-Y. Yang, E. Tung, G. Karsenty, and C. M. Giachelli Inactivation of the Osteopontin Gene Enhances Vascular Calcification of Matrix Gla Protein-deficient Mice: Evidence for Osteopontin as an Inducible Inhibitor of Vascular Calcification In Vivo J. Exp. Med., October 21, 2002; 196(8): 1047 - 1055. [Abstract] [Full Text] [PDF]

				F. Parhami, B. Basseri, J. Hwang, Y. Tintut, and L. L. Demer High-Density Lipoprotein Regulates Calcification of Vascular Cells Circ. Res., October 4, 2002; 91(7): 570 - 576. [Abstract] [Full Text] [PDF]

				L. L Demer Vascular calcification and osteoporosis: inflammatory responses to oxidized lipids Int. J. Epidemiol., August 1, 2002; 31(4): 737 - 741. [Full Text] [PDF]

				Y. Tintut, J. Patel, M. Territo, T. Saini, F. Parhami, and L. L. Demer Monocyte/Macrophage Regulation of Vascular Calcification In Vitro Circulation, February 5, 2002; 105(5): 650 - 655. [Abstract] [Full Text] [PDF]

				D. J. Klemm, P. A. Watson, M. G. Frid, E. C. Dempsey, J. Schaack, L. A. Colton, A. Nesterova, K. R. Stenmark, and J. E.-B. Reusch cAMP Response Element-binding Protein Content Is a Molecular Determinant of Smooth Muscle Cell Proliferation and Migration J. Biol. Chem., November 30, 2001; 276(49): 46132 - 46141. [Abstract] [Full Text] [PDF]

				M. A Engelse, J. M Neele, A. L.J.J Bronckers, H. Pannekoek, and C. J.M de Vries Vascular calcification: expression patterns of the osteoblast-specific gene core binding factor {alpha}-1 and the protective factor matrix gla protein in human atherogenesis Cardiovasc Res, November 1, 2001; 52(2): 281 - 289. [Abstract] [Full Text] [PDF]

				Y. Tintut, J. Patel, F. Parhami, and L. L. Demer Tumor Necrosis Factor-{alpha} Promotes In Vitro Calcification of Vascular Cells via the cAMP Pathway Circulation, November 21, 2000; 102(21): 2636 - 2642. [Abstract] [Full Text] [PDF]

				Y. Tintut, F. Parhami, V. Le, G. Karsenty, and L. L. Demer Inhibition of Osteoblast-specific Transcription Factor Cbfa1 by the cAMP Pathway in Osteoblastic Cells. UBIQUITIN/PROTEASOME-DEPENDENT REGULATION J. Biol. Chem., October 8, 1999; 274(41): 28875 - 28879. [Abstract] [Full Text] [PDF]

				S. M. Jackson, F. Parhami, X.-P. Xi, J. A. Berliner, W. A. Hsueh, R. E. Law, and L. L. Demer Peroxisome Proliferator–Activated Receptor Activators Target Human Endothelial Cells to Inhibit Leukocyte–Endothelial Cell Interaction Arterioscler. Thromb. Vasc. Biol., September 1, 1999; 19(9): 2094 - 2104. [Abstract] [Full Text] [PDF]

				A. J. Koh, C. A. Beecher, T. J. Rosol, and L. K. McCauley 3',5'-Cyclic Adenosine Monophosphate Activation in Osteoblastic Cells: Effects on Parathyroid Hormone-1 Receptors and Osteoblastic Differentiation in Vitro Endocrinology, July 1, 1999; 140(7): 3154 - 3162. [Abstract] [Full Text]

				M. D. Rekhter Collagen synthesis in atherosclerosis: too much and not enough Cardiovasc Res, February 1, 1999; 41(2): 376 - 384. [Abstract] [Full Text] [PDF]

				F. Parhami, Y. Tintut, A. Ballard, A. M. Fogelman, and L. L. Demer Leptin Enhances the Calcification of Vascular Cells : Artery Wall as a Target of Leptin Circ. Res., May 11, 2001; 88(9): 954 - 960. [Abstract] [Full Text] [PDF]

				S. A. Steitz, M. Y. Speer, G. Curinga, H.-Y. Yang, P. Haynes, R. Aebersold, T. Schinke, G. Karsenty, and C. M. Giachelli Smooth Muscle Cell Phenotypic Transition Associated With Calcification: Upregulation of Cbfa1 and Downregulation of Smooth Muscle Lineage Markers Circ. Res., December 7, 2001; 89(12): 1147 - 1154. [Abstract] [Full Text] [PDF]

This Article Abstract Full Text (PDF) Submit a Letter to Editor Alert me when this article is cited Alert me when eLetters are posted Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Tintut, Y. Articles by Demer, L. L. Search for Related Content PubMed PubMed Citation Articles by Tintut, Y. Articles by Demer, L. L. Social Bookmarking                      What's this?